Uncovering the Emotional and Mental Impact of Psoriatic Disease
Congressional Briefing Addresses Quality of Life Concerns for Psoriatic Disease Patients
WASHINGTON (April 19, 2016) — To ensure that people living with psoriasis and psoriatic arthritis have access to the treatments needed to manage their disease, the National Psoriasis Foundation (NPF) will hold a congressional briefing today to address the emotional and mental implications of psoriatic disease.
This briefing will include Cyndi Lauper, pop icon and spokeswoman for “I'm PsO Ready,” a national initiative driven by NPF and Novartis Pharmaceuticals Corporation to highlight the physical, emotional and social challenges of psoriasis. The briefing will also include NPF medical board member, board-certified dermatologist and clinical psychologist Dr. Richard Fried of Yardley Dermatology and Yardley Clinical Research Associates.
In addition to dealing with the physical suffering and an increased risk of comorbidities, such as cardiovascular disease and diabetes, many patients struggle with depression and a reduced quality of life due to the social stigma associated with psoriatic disease.
Recent studies have found that those living with psoriasis have a 39 percent increased risk of being diagnosed with depression than those without the disease1. Those with a combination of both psoriasis and psoriatic arthritis suffer higher rates of anxiety and depression than those with psoriasis alone2.
For many, treating their disease is the first step in reducing the risk of depression and improving overall quality of life. However, lack of access, lack of appropriate diagnosis, and lack of resources to get medication limit many patients from treating their disease. Congress can help address these issues by removing barriers that are making it hard for patients to treat their disease.
“The goal of this briefing is to ask Congress to support initiatives that provide better access for patients to effectively treat their disease, said Randy Beranek, president of the National Psoriasis Foundation. “By addressing the significant impact psoriatic disease has on patients’ overall quality of life, we are getting closer to achieving our goal of dramatically improving health outcomes for all with psoriatic disease.”
1Arch Dermatol. 2010 Aug; 146(8):891-5. doi: 10.1001/archdermatol.2010.186.
The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.
Kurd SK1, Troxel AB, Crits-Christoph P, Gelfand JM.
2J Rheumatol. 2014 May; 41(5):887-96. doi: 10.3899/jrheum.130797. Epub 2014 Apr 1.
Depression and anxiety in psoriatic disease: prevalence and associated factors.
McDonough E1, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD.
About the National Psoriasis Foundation
Serving its community through more than 50 years of patient support, advocacy, research, education, and funding, the National Psoriasis Foundation (NPF) is the world’s leading nonprofit fighting for individuals with psoriasis and psoriatic arthritis. The NPF mission is to drive efforts to cure psoriatic disease and dramatically improve the lives of more than 8 million individuals in the United States affected by this chronic immune-mediated disease. As part of that effort, NPF created its Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. To date, NPF has funded more than $21 million in research grants and fellowships that help drive discoveries that may lead to more and better treatments and ultimately a cure. Learn more at www.psoriasis.org.